# OnCo record paper-oreilly-durvalumab-tremelimumab-pancreatic-jama-oncol-2019 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-oreilly-durvalumab-tremelimumab-pancreatic-jama-oncol-2019/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-oreilly-durvalumab-tremelimumab-pancreatic-jama-oncol-2019" ;
  schema:name "Durvalumab with or without tremelimumab for patients with metastatic pancreatic ductal adenocarcinoma: a phase 2 randomized clinical trial"@en ;
  schema:description "Giving 65 patients with advanced pancreatic cancer a PD-L1 antibody alone or with a CTLA-4 antibody shrank tumours in 3% and 0%, so the trial was stopped before its second stage."@en ;
  schema:url <https://onco.cc/key-papers/paper-oreilly-durvalumab-tremelimumab-pancreatic-jama-oncol-2019/> ;
  schema:dateModified "2026-09-24"^^xsd:date ;
  schema:citation <https://doi.org/10.1001/jamaoncol.2019.1588>, <https://pubmed.ncbi.nlm.nih.gov/31318392/> ;
  schema:sameAs <https://doi.org/10.1001/jamaoncol.2019.1588> ;
  schema:datePublished "2019"^^xsd:gYear ;
  schema:author "O'Reilly EM, Oh DY, Dhani N, et al." ;
  onco:cancers <https://onco.cc/cancers/pancreatic/>, <https://onco.cc/cancers/metastatic-pdac/> ;
  onco:targets <https://onco.cc/targets/pdl1/>, <https://onco.cc/targets/ctla4/> ;
  onco:drugs <https://onco.cc/drugs/durvalumab/> ;
  onco:institutions <https://onco.cc/institutions/mskcc/> ;
  onco:pathways <https://onco.cc/pathways/pd1-checkpoint/> ;
  onco:terms <https://onco.cc/terms/cold-vs-hot/> ;
  onco:people <https://onco.cc/people/eileen-oreilly/> ;
  onco:journals <https://onco.cc/journals/jama-oncology/> .